Mark Hopman Sells 36,870 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 36,870 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20. Following the completion of the sale, the insider owned 87,157 shares of the company’s stock, valued at $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total value of $18,882.58.

Beta Bionics Stock Down 4.8%

Shares of NASDAQ:BBNX traded down $0.83 on Thursday, reaching $16.59. The company had a trading volume of 957,710 shares, compared to its average volume of 1,143,668. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The stock has a 50-day moving average price of $17.30 and a 200 day moving average price of $13.76. The stock has a market capitalization of $746.38 million, a P/E ratio of -10.05 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. On average, sell-side analysts predict that Beta Bionics, Inc. will post -2.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Beta Bionics

Institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC lifted its holdings in shares of Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after buying an additional 240,000 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Beta Bionics in the second quarter valued at approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Beta Bionics in the fourth quarter valued at approximately $40,437,000. Bruce & Co. Inc. acquired a new stake in shares of Beta Bionics in the first quarter worth $5,518,000. Finally, Y Intercept Hong Kong Ltd grew its stake in shares of Beta Bionics by 4,236.8% in the first quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock worth $4,868,000 after acquiring an additional 474,651 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BBNX shares. William Blair began coverage on Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating for the company. The Goldman Sachs Group lifted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Truist Financial boosted their price objective on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, UBS Group initiated coverage on shares of Beta Bionics in a report on Tuesday, July 28th. They set a “buy” rating and a $22.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.10.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Several law firms reminded investors that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a federal securities class action filed in the U.S. District Court for the Central District of California. The proposed class covers investors who purchased Beta Bionics securities from July 30, 2025, through February 24, 2026. Johnson Fistel investor alert
• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain officers misled investors about quality and safety issues involving its iLet insulin pump. According to the allegations, company filings characterized an FDA Warning Letter as identifying quality-management-system “non-conformities” while failing to disclose the extent of unreported iLet complaints, including complaints allegedly involving life-threatening hypoglycemia. These claims have not been proven in court. SueWallSt shareholder alert
• Negative Sentiment: The complaints further allege that analyst commentary remained favorable after the FDA Warning Letter because it relied on company statements that minimized the issue. If the claims succeed, Beta Bionics could face financial damages, legal expenses, regulatory scrutiny and reputational harm, creating additional uncertainty for the loss-making medical-device company. Levi and Korsinsky shareholder alert

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.